PT - JOURNAL ARTICLE AU - Louise Emsell AU - Heleen Vanhaute AU - Kristof Vansteelandt AU - François-Laurent De Winter AU - Danny Christiaens AU - Jan Van den Stock AU - Rik Vandenberghe AU - Koen Van Laere AU - Stefan Sunaert AU - Filip Bouckaert AU - Mathieu Vandenbulcke TI - An optimized MRI and PET based clinical protocol for improving the differential diagnosis of Geriatric Depression and Alzheimer’s Disease AID - 10.1101/2021.02.08.21251205 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.08.21251205 4099 - http://medrxiv.org/content/early/2021/02/09/2021.02.08.21251205.short 4100 - http://medrxiv.org/content/early/2021/02/09/2021.02.08.21251205.full AB - OBJECTIVE MRI derived hippocampal volume (HV) and amyloid PET may be useful clinical biomarkers for differentiating between geriatric depression and Alzheimer’s Disease (AD). Here we investigated the incremental value of HV and 18F-flutemetmol PET in tandem and sequentially to improve discrimination in unclassified participants.METHOD Two approaches were compared in 41 participants with geriatric depression and 27 participants with probable AD: (1) amyloid and HV combined in one model and (2) HV first and then amyloid.RESULTS Both HV(χ2(1) = 6.46: p= 0.011) and amyloid (χ2(1) =11.03: p=0.0009) were significant diagnostic predictors of depression (sensitivity: 95%, specificity: 89%). (2) 51% of participants were correctly classified according to clinical diagnosis based on HV alone, increasing to 87% when adding amyloid data (sensitivity: 94%, specificity: 78%).CONCLUSION Hippocampal volume may be a useful gatekeeper for identifying depressed individuals at risk for AD who would benefit from additional amyloid biomarkers when available.Competing Interest StatementRV has a consultancy agreement from AC Immune, and his institution has a clinical trial agreement with AbbVie and Roche. K. Van Laere has received contract research grants through KU Leuven from Merck, Janssen Pharmaceuticals, Abide, UCD, Cerveau, Syndesi, Eikonizo, GE Healthcare, and Curasen; he has received speaker fees from GE Healthcare. Part of the data used in this study was derived from a GE-sponsored phase II clinical trial. The sponsors had no role in the study design; collection, analysis, or interpretation of data; nor imposed any restrictions regarding the submission of this report for publicationFunding StatementThis study was supported by Research Foundation Flanders (FWO) project G074609, and Research Grant Old Age Psychiatry UZ Leuven R94859. The tracer [18F]-flutemetamol was provided free of charge by GE for this investigator-led analysis. Additionally, MV, FB, LE have received funding from the FWO (G0C0319N), and along with JVdS are supported by KU Leuven: C24/18/095 and The Sequoia Fund. RV has received funding from the Foundation for Alzheimer Research (SAO-FRMA) (09013, 11020, 13007) and KU Leuven OT/08/056, OT/12/097Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UZ Leuven Ethics Committee (S52151)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on reasonable request from the corresponding author